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Research on the lymphatic vascular system has advanced
rapidly during the last decade, and lymphatic dysfunction is
now implicated in the pathogenesis of multiple diseases.
This review provides an overview of the lymphatic vascular
system in the liver.
The lymphatic vascular systemhasbeenminimally explored
in the liver despite its essential functions including main-
tenance of tissue ﬂuid homeostasis. The discovery of spe-
ciﬁc markers for lymphatic endothelial cells has advanced
the study of lymphatics by methods including imaging, cell
isolation, and transgenic animal models and has resulted in
rapid progress in lymphatic vascular research during the
last decade. These studies have yielded concrete evidence
that lymphatic vessel dysfunction plays an important role in
the pathogenesis of many diseases. This article reviews the
current knowledge of the structure, function, and markers
of the hepatic lymphatic vascular system as well as fac-
tors associated with hepatic lymphangiogenesis and com-
pares liver lymphatics with those in other tissues. (Cell Mol
Gastroenterol Hepatol 2016;2:733–749; http://dx.doi.org/
10.1016/j.jcmgh.2016.09.002)
Keywords: VEGF; Inﬂammation; Cirrhosis; Portal Hypertension.
he lymphatic and blood vascular systems togetherAbbreviations used in this paper: CCl4, carbon tetrachloride; EHE,
epithelioid hemangioendothelioma; HA, hyaluronan; HBx Ag, hepatitis
B x antigen; HCC, hepatocellular carcinoma; IFN, interferon; IL, inter-
leukin; LSEC, liver sinusoidal endothelial cell; LyEC, lymphatic endo-
thelial cell; LYVE-1, lymphatic vessel endothelial hyaluronan receptor
1; mTOR, mammalian target of rapamycin; NO, nitric oxide; Prox1,
prospero homeobox protein 1; VEGF, vascular endothelial growth
factor; VEGFR, vascular endothelial growth factor receptor.
Most current article
© 2016 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2352-345X
http://dx.doi.org/10.1016/j.jcmgh.2016.09.002Tconstitute the circulatory system, and both have
essential physiological activities. The lymphatic vascular
system maintains tissue ﬂuid homeostasis by collecting
excess tissue ﬂuid and returning it to the venous circulation.
It also plays an essential role in the absorption and trans-
port of dietary fat. Furthermore, lymphatics serve as the
main conduits of antigens and antigen-presenting cells from
the periphery to lymph nodes and are thus crucial for
immune surveillance and acquired immunity.1–4
Lymphatic vascular research was impeded by a lack of
knowledge about the markers and signaling pathways spe-
ciﬁc to the lymphatic vasculature. From 1995 to 1997,
however, it was shown that vascular endothelial growth
factor receptor (VEGFR)-3 is expressed in the lymphatic
endothelium and that its ligand vascular endothelial growth
factor (VEGF)-C promotes lymphangiogenesis.5,6 This
ﬁnding identifying signaling pathways speciﬁc to the
lymphatic vasculature and subsequent discoveries of other
speciﬁc markers for lymphatic endothelial cells (LyECs),such as lymphatic vessel endothelial hyaluronan receptor 1
(LYVE-1),7 prospero homeobox protein 1 (Prox1),8 and
podoplanin,9 signiﬁcantly advanced lymphatic vascular
research. As a consequence, it is now recognized that
lymphatic vessel dysfunction plays an important role in the
pathogenesis of various diseases.
However, in the liver, the lymphatic vascular system has
been little explored. This review will provide an overview of
the structure, function, and markers of the lymphatic
vascular system as well as factors associated with lym-
phangiogenesis in the liver, highlighting both new ﬁndings
and areas needing further study.
Structure of the Hepatic Lymphatic
Vascular System
This section will address the structure of the lymphatic
vascular system in general, followed by structural features
speciﬁc to the liver. A detailed description of the anatomic
structure of the lymphatic and hepatic lymphatic vascular
systems is available in other review articles.3,10–12
Anatomy of the Lymphatic Vascular System
Lymphatic capillaries. Lymphatic ﬂuid originates from
plasma components leaked from blood capillaries into the
interstitium and then enters lymphatic capillaries, which are
blind-ended, thin-walled vessels consisting of a single layer of
LyECs. Lymphatic capillaries are not covered by pericytes or
smooth muscle cells and lack basement membranes.13,14
They are highly permeable, with discontinuous “button-
like” junctions through which interstitial ﬂuid, macromole-
cules, and immune cells can be transported.15 LyECs have
anchoring ﬁlaments that are mainly composed of emilin-1
and ﬁbrillin and bind LyECs to the surrounding extracel-
lular matrix.14,16,17 These ﬁlaments keep lymphatic vessel
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swelling.
Collecting vessels. Lymphatic capillaries coalesce into
collecting vessels, which are covered with smooth muscle
cells and have basement membranes.14 Collecting vessels
lack the discontinuous junctions typical of lymphatic capil-
laries and are thus much less permeable. Collecting vessels
can be divided into smaller functional units called lym-
phangions that have unidirectional bicuspid valves at each
end.18 The phasic contraction of smoothmuscle cells covering
lymphangions enables collecting vessels to act as pumps to
drive lymphatic ﬂow. Stimulation of smooth muscle cells
causes depolarization of cell membrane and opens Ca2þ
channels, resulting in Ca2þ inﬂux and smooth muscle cell
contraction. Smooth muscle cells also have stretch-activated
Ca2þ channels that facilitate phasic contraction.19,20 On theFigure 1. Schematic diagram of macro-anatomy of hepatic lym
tract coalesce into collecting vessels, which drain to lymph n
lymphatic vessels (LV) from these lymph nodes connect to celia
origin of the thoracic duct. Lymphatic ﬂuid through the thoraci
systemic blood circulation. (2) Lymphatic vessels along the cen
hepatic vein (HV), which then traverse along the inferior vena
nodes. (3) Lymphatic ﬂuid running underneath the capsule of th
nodes through the coronary ligament, whereas that of the conca
regional lymph nodes. BD, bile duct; HA, hepatic artery; LN, lymother hand, LyECs produce the vasodilator nitric oxide (NO)
in response to shear stress from ﬂuid ﬂow, counteracting
Ca2þ-dependent contraction.21,22 Spatiotemporal alterations
of Ca2þ and NO levels are thereby believed to modulate the
phasic contraction of lymphangions.23
Lymph nodes and lymph trunks. Collecting vessels
connect to 1 or more lymph nodes. Antigen-presenting cells
including dendritic cells and macrophages in lymphatic ﬂuid
interact with lymphocytes in lymph nodes, facilitating adap-
tive immune responses. After reaching primary lymph nodes,
lymphatic ﬂuid ﬂows to secondary central lymph nodes,
tertiary central lymph nodes, and ﬁnally lymph trunks.24
Lymphatic ﬂuid from the left side of the body, abdomen,
and lower limb ultimately drains into the thoracic duct, the
largest lymphatic vessel, which is connected to the left sub-
clavian vein (Figure 1), whereas lymphatic ﬂuid from otherphatic vascular system. (1) Lymphatic capillaries in the portal
odes at the hepatic hilum and the lesser omentum. Efferent
c lymph nodes, which drain to the cisterna chyli, the enlarged
c duct drains to the left subclavicular vein and returns to the
tral vein (CV) converge into large lymphatic vessels along the
cava (IVC) through the diaphragm toward mediastinal lymph
e convex surface of the liver (3i) drains to mediastinal lymph
ve surface (3ii) drains to lymph nodes of the hepatic hilum and
ph node; PV, portal vein.
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connected to the right subclavian vein.25 Lymphatic ﬂuid that
enters the subclavian veins returns to the systemic blood
circulation.Anatomy of the Hepatic Lymphatic
Vascular System
A schematic diagram of the hepatic lymphatic system is
shown in Figures 1 and 2. Unlike other tissues, the liver has
sinusoids instead of capillaries.26 Sinusoids, similar to
lymphatic capillaries, are distinct from blood capillaries in
that they consist of 1 layer of liver sinusoidal endothelial
cells (LSECs) and lack basement membranes. Hepatic
lymphatic ﬂuid is thought to originate from plasma com-
ponents ﬁltered through the fenestrae of LSECs into the
space of Disse, the interstitial space between LSECs and
hepatocytes.10,11 Fluid in the space of Disse primarily ﬂows
through the space of Mall, a space between the stroma of
the portal tract and the outermost hepatocytes,27 into the
interstitium of the portal tract and then into lymphatic
capillaries. Some portion of the ﬂuid in the space of Disse
ﬂows into the interstitium around the central vein, which is
located in the center of the liver acinus and connected to
the hepatic vein,28 or underneath the hepatic capsule
(Figure 2).
Lymphatic capillaries in the portal tract coalesce into
collecting vessels and drain to lymph nodes at the hepatic
hilum, whereas lymphatic vessels along the central veinFigure 2. Schematic diagram of the micro-anatomy of the hepat
portal vein (PV) and hepatic artery (HA) enters the liver. Plasma c
the interstitial space between LSECs and hepatocytes, and are re
space of Disse mostly ﬂows through the space of Mall, the spa
hepatocytes, into the interstitium of the portal tract and then into
the space of Disse ﬂows into the interstitium around the centraconverge into 5–6 large lymphatic vessels that traverse
along the inferior vena cava through the diaphragm toward
posterior mediastinal lymph nodes. Lymphatic ﬂuid running
underneath the capsule of the convex surface of the liver
drains to mediastinal lymph nodes through the coronary
ligament, whereas that ﬂuid running along the concave
surface drains to lymph nodes in the hepatic hilum and to
regional lymph nodes (Figure 1).10–12,29 On the basis of their
locations, lymphatic vessels along the portal tract and the
central vein are called the deep lymphatic system, and those
along the hepatic capsule are called the superﬁcial
lymphatic system.10–12,29Markers of Lymphatic Vessels
Lymphatic vessel markers generally refer to those spe-
ciﬁc to LyECs. The markers LYVE-1,7,30,31 podoplanin,9,32
Prox1,8,33–35 and VEGFR-35 are most commonly used for
microscopic imaging of lymphatic vessels.36 Identiﬁcation of
more speciﬁc markers for the liver is needed because the
most common LyEC markers, LYVE-1 and Prox1, are also
expressed in LSECs and hepatocytes, respectively. Table 1
summarizes LyEC markers histologically examined in the
liver.
Lymphatic vessel endothelial hyaluronan receptor
1. LYVE-1 is a lymphatic vessel endothelial hyaluronan
(HA) receptor, a homolog of the CD44 HA receptor,7 that
belongs to the superfamily of Link proteins containing a
conserved HA-binding domain known as the Link module.37ic lymphatic vascular system. Blood ﬂow (red arrows) from the
omponents are ﬁltered through LSECs into the space of Disse,
garded as the source of lymphatic ﬂuid. Lymphatic ﬂuid in the
ce between the stroma of the portal tract and the outermost
lymphatic capillaries (1). Some portion of the lymphatic ﬂuid in
l vein (2) or underneath the hepatic capsule (3).
Table 1.Lymphatic Markers
Marker
Postnatal expression except for lymphatic vessels
Hepatic expression in
pathologic conditions ReferenceLiver Other organs/cells
LYVE-1 Sinusoidal
endothelial cells
A portion of macrophages,
pulmonary capillaries,
epididymal adipose
tissue, mesentery, eye
(cornea, sclera,
choroid, iris, and retina),
wounded skin, and
malignant tumors
(melanoma and
insulinoma)
In chronic hepatitis and
liver cirrhosis in
humans, LYVE-1(þ)
lymphatic vessels
increase, but LYVE-1(þ)
sinusoidal endothelial
cells decrease.
38, 40–43,
105, 159–164
Prox1 Hepatocytes Adrenal medulla,
megakaryocytes, and
platelets
Intrahepatic CCC, ductular
cells in cirrhotic livers,
and HCC in humans.
8, 52, 58, 59
Podoplanin Cholangiocytes Inﬂammatory
macrophages,
mesothelial cells,
cardiomyocytes, FRCs,
follicular dendritic cells,
TH17 cells, and
osteoblasts
Podoplanin(þ) lymphatic
vessels increase in
decompensated
cirrhosis in humans.
Podoplanin(þ) FRCs
increase in livers of
primary biliary cirrhosis
patients. EHE and
angiomyolipoma in
humans.
32,72, 75–79,
165, 166
VEGFR-3 Cholangiocytes A portion of macrophages,
proliferating blood
vessels, and
fenestrated capillaries
in endocrine glands,
choroid plexus, kidney,
and small intestine
HBx Ag–positive HCC and
hepatic progenitor cells
in primary biliary
cirrhosis in humans.
80, 83–85,
102, 167, 168
CCL21 Sinusoidal
endothelial cells
A portion of dendritic cells,
HEVs of lymph nodes
and Peyer’s patches,
T-cell areas of spleen,
lymph nodes, and
Peyer’s patches
Lymphoid tissue in primary
biliary cirrhosis and
primary sclerosing
cholangitis in humans.
169–171
MMR1 Sinusoidal
endothelial cells
and Kupffer cells
A portion of macrophages,
sinusoidal endothelial
cells in bone marrow
and spleen,
perivascular microglia,
and glomerular
mesangial cells
Unknown 172–175
Desmoplakin Basolateral plasma
membrane of
hepatocytes and
cholangiocytes
Esophagus, intestine,
colon, salivary gland,
mammary gland, sweat
gland, thymus, and
endocervix
Entire plasma membrane
of HCC cells
174, 176–179
Integrin a9 Hepatocytes Airway epithelial cells,
keratinocytes, muscle
cells (smooth/skeletal/
cardiac), neutrophils,
osteoclasts, and
oocytes
Unknown 174, 180
CCC, cholangiocellular carcinoma; CCL21, C-C motif chemokine ligand 21; FRC, ﬁbroblastic reticular cell; HEV, high
endothelial venules; MMR, macrophage mannose receptor 1.
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in the transport of HA across the lymphatic endothelium.
LYVE-1 is strongly expressed on the entire luminal and
abluminal surfaces of LyECs, even on the ﬁne ﬁlopodia of
growing vessels during lymphangiogenesis.
No deﬁnite alterations in lymphatic vessel structure
and function were reported for LYVE-1–/– mice.38 How-
ever, diphtheria toxin-induced LYVE-1 depletion in mice
caused acute loss of lymphatic lacteals in intestinal villi
and lymphatic vessels in systemic lymph nodes. These
changes resulted in the structural distortion of blood
capillaries and villi, leading to death due to sepsis within
60 hours after LYVE-1 depletion.39 These observations
indicate that LYVE-1 plays an important role in the
maintenance of the lymphatic vascular system, especially
lacteals in intestinal villi and lymph nodes. Compensa-
tory mechanisms in the setting of congenital loss of
LYVE-1 may explain the relatively mild phenotype of
these mice.
In the liver, LYVE-1 is expressed not only in LyECs but
also in LSECs, as shown in mice40 and humans.40–43 How-
ever, LYVE-1 positivity in LSECs was reported to diminish in
inﬂamed human livers such as those of chronic hepatitis and
cirrhosis.40,42 Expression levels of LYVE-1 in human hepa-
tocellular carcinoma (HCC) negatively correlated with the
overall survival of patients.44
Prospero homeobox protein 1. Prox1, a homolog of the
Drosophila melanogaster homeobox gene prospero, is a
transcription factor and regulates genes related to LyECs,
including VEGFR-3 and podoplanin.45,46 Prox1 is essential for
the development of the lymphatic vascular system8 and also
plays a role in the development of other tissues, including the
lens,34,47 retina,48 heart,49 central nervous system,50
pancreas,51 and liver.52,53 Prox1 is expressed in the nucleus
in contrast to other lymphatic markers that are expressed in
the cytoplasm or on the plasma membrane.
Prox1 is essential for budding of lymphatic endothelial
sacs8; Prox1–/–mice lack a lymphatic vascular system and die
at approximately E14.5. Prox1 heterozygote mice die a few
days after their birth and demonstrate dysfunction of
lymphatic vessels with chylous ascites.8,33,47 Several lines of
Prox1 promoter-directed reporter mice have recently been
established as research tools (GFP,54 mOrange,55 and
tdTomato56–58).
In the early endoderm, Prox1 expression is restricted to
the primordia of the liver and pancreas.51 Prox1 regulates
hepatocyte migration during liver morphogenesis51 and is
expressed in postnatal hepatocytes, although not in post-
natal pancreas.52 In humans, cholangiocytes of normal livers
were negative for Prox1 expression, but intrahepatic chol-
angiocarcinoma and ductular cells in ﬁbrotic septa of
cirrhotic livers and HCC were positive.59 In addition,
expression levels of Prox1 (like LYVE1) in human HCC
negatively correlated with the overall survival of patients.60
Prox1 acts together with nuclear receptors, such as hepa-
tocyte nuclear factor 4a,61 estrogen-related receptor a,62,63
liver receptor homolog-1,64 and retinoic acid-related orphan
receptors a/g,65 and regulates bile acid synthesis64 and
circadian metabolism in the liver.63,65Podoplanin. Podoplanin is a type I transmembrane
glycoprotein essential for the development of the heart,66–69
lung,70 spleen, and lymph nodes.71 Its expression is regu-
lated by Prox1.45 Podoplanin is also a ligand of C-type lectin
receptor CLEC-2, which is highly expressed in platelets and
immune cells and promotes platelet aggregation and
activation.72
Podoplanin–/– mice die at birth as a result of respiratory
failure. These mice have congenital lymphedema caused
by lymphatic vessel defects, although blood vessel formation
is normal.32 Podoplanin heterozygote mice are healthy and
fertile, with a partial incomplete lymphatic vessel network.32
Keratinocyte-speciﬁc podoplanin-deﬁcient mice73 and a
tamoxifen-inducible podoplanin depletion mouse model
(Pdpnf/f, CagCre)74 have recently been developed.
Histologic analysis of normal mouse livers showed
expression of podoplanin in cholangiocytes in addition
to LyECs.75 In humans, podoplanin-positive lymphatic ves-
sels were increased in the livers of patients with decom-
pensated cirrhosis,76 and podoplanin-positive ﬁbroblastic
reticular cells were increased in livers of patients with
primary biliary cirrhosis.77 Podoplanin has proven to be a
useful histologic marker for diagnosing patients who have
vascular tumors with lymphatic differentiation, such as
epithelioid hemangioendotheliomas (EHEs)78 and
angiomyolipomas.79
Vascular endothelial growth factor receptor. VEGFR-3
is a membrane-anchored tyrosine kinase and the receptor
for VEGF-C and VEGF-D. It plays a crucial role in lym-
phangiogenesis. In early embryogenesis before LyEC dif-
ferentiation, VEGFR-3 is expressed in most endothelial cells,
but in the later stages of development, its expression be-
comes mostly restricted to the lymphatic endothelium.5
VEGFR-3–/– mice have lymphatic vessel defects and die
at approximately E10.5,80 whereas VEGFR-3 heterozygous
mice present with leaky lymphatic vessels and transient
chylous ascites.80,81 A mouse line (Vegfr3EGFPLuc) in which a
dual reporter for ﬂuorescence and luminescence is
expressed under VEGFR-3-promoter was established
recently, enabling luminescence imaging of tumor-induced
lymphangiogenesis.82
VEGFR-3 is expressed by cholangiocytes in normal rat
livers and is increased in cholestatic rat livers after bile duct
ligation.83 Hepatic progenitor cells were also found to ex-
press VEGFR-3 in patients with primary biliary cirrhosis.84
Hepatitis B x antigen (HBx Ag), one of the antigens of hep-
atitis B virus, promotes hepatocarcinogenesis by upregu-
lating expression of genes associated with proliferation of
hepatocytes; upregulation of VEGFR-3 expression was
observed in HBx Ag–positive human HCC, and the prognosis
of patients with VEGFR-3–positive HCC was worse than for
those with VEGFR-3–negative HCC.85Lymphangiogenesis
This section addresses the mechanism of lymphangio-
genesis in the postnatal stage and factors that affect lym-
phangiogenesis, including inﬂammatory cells, in the
lymphatic system in general and then summarizes the
738 Tanaka and Iwakiri Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 6implications of lymphangiogenesis in the pathophysiology of
liver diseases.
Factors Associated With Lymphangiogenesis
In the postnatal stage, lymphatic vessels are mostly
quiescent, and lymphangiogenesis generally occurs in
pathologic conditions such as tissue repair, inﬂammation,
and tumor-related conditions.86 Many cytokines and growth
factors have been reported to promote lymphangiogenesis
or inhibit lymphangiogenesis, as summarized in Table 2. The
extent and duration of lymphangiogenesis are determined
by the balance between pro- and anti- lymphangiogenic
factors.87,88
Intracellular Signaling Pathways in
Lymphangiogenesis
Signaling pathways in lymphangiogenesis have largely
been determined in studies of developmental lymphangio-
genesis. Signaling via VEGF-C/D and VEGFR-3 is the most
well-known pathway for lymphangiogenesis (Figure 3).6
VEGF-C or VEGF-D binding to VEGFR-3 results in auto-
phosphorylation of multiple C-terminal tyrosine residues in
VEGFR-3,89 which transduces signals through the Ras/Raf/
MEK/ERK pathway.90 Signal transduction also occurs
through the PI3K/Akt pathway,91 which causes phosphor-
ylation of Akt, thereby activating mammalian target of
rapamycin (mTOR) and Rac1.92 Activation of these signaling
pathways facilitates LyEC proliferation and migration, ie,
lymphangiogenesis.91 Chronic inﬂammation and malignant
tumors in the liver induce several pro-lymphangiogenic
growth factors including VEGF-C/D. However, a direct link
between these increased pro-lymphangiogenic growth fac-
tors and lymphangiogenesis in these pathologic conditions
remains to be demonstrated (Figure 3). Excellent review
articles are available detailing signaling pathways in
lymphangiogenesis.93–95
Role of Immune Cells
Adaptive immune responses are initiated by the migra-
tion of immune cells to inﬂamed sites where they phago-
cytose pathogens and transmigrate through lymphatic
vessels to lymph nodes to present antigens to T cells.
However, immune cells not only migrate through lymphatic
vessels but also interact with lymphatic vessels and pro-
mote lymphangiogenesis.96 An increase in lymphatic vessels
helps inﬁltrating immune cells exit inﬂamed sites via
lymphatic vessels and accelerates resolution of
inﬂammation.97–99
Macrophages. Among the various immune cells, macro-
phages interact most with lymphatic vessels. LyECs secrete
chemotactic factors, such as C10, monocyte chemoattractant
protein-1, and macrophage inﬂammatory protein-1, to
attract macrophages.100 Macrophages in turn secrete lym-
phangiogenic cytokines such as VEGF-C, VEGF-D, and
VEGF-A,101 which promote tumor-associated lymphangio-
genesis102 and inﬂammation-induced lymphangiogenesis, as
shown in the cornea,103 skin,98 and tail.104 Macrophages
were recently suggested to have the ability totransdifferentiate to LyECs.105–107 However, this is contro-
versial and requires further investigation.
Dendritic cells. Upregulation of inﬂammatory cytokines
such as tumor necrosis factor-a and interleukin (IL) 1b in
inﬂamed tissues promotes expression of chemokines (eg,
CCL21/CCL19 and CXCL12) and their receptors (eg, CCR7
and CXCR-4) in LyECs and dendritic cells,108–111 which en-
hances transmigration of dendritic cells through
LyECs.112,113 Inﬂammatory cytokines also increase expres-
sion of adhesion molecules such as intercellular adhesion
molecule 1, vascular cell adhesion molecule 1, and E-selectin
in LyECs and promote dendritic cell transmigration to
lymphatic vessels.114 Dendritic cells have also been reported
to secrete VEGF-C and promote lymphangiogenesis.115
T cells. In a mouse model of tail lymphedema, nude mice
exhibited less edema than wild-type mice, concomitant with
decreased lymphangiogenic cytokines and increased anti-
lymphangiogenic cytokines. The balance between these
cytokines was modulated by T-cell–mediated inﬂamma-
tion.88 T cells negatively regulated lymph node lym-
phangiogenesis by secreting interferon (IFN)-g in mice.116
B cells. B cells promote lymphangiogenesis in inﬂamed
lymph nodes by secreting a robust amount of VEGF-A in
mice given keyhole-limpet hemocyanin emulsiﬁed
in complete Freund’s adjuvant (an experimental model
of inﬂamed lymph nodes).117 Interestingly, VEGF-C was
not detected in this study. Another study that used
transgenic mice overexpressing VEGF-A speciﬁcally in B
cells showed increased lymphangiogenesis as well as
angiogenesis.118
Neutrophils. Neutrophils are reported to contribute to
lymphangiogenesis by modulating the bioavailability and
bioactivity of VEGF-A and by secreting VEGF-D.119 The
bioavailability of VEGF-A is increased by the secretion of
matrix metalloproteinases 9 and heparanase. Depletion of
neutrophils in mice resulted in skin inﬂammation in
response to immunization or contact hypersensitization,
and lymphangiogenesis was decreased in these mice with
increased local inﬂammation, suggesting that neutrophils
play a role in lymphangiogenesis and that lymphangio-
genesis is helpful for reducing inﬂammation.Lymphangiogenesis in the Liver
Because 25%–50% of lymph passing through the thoracic
duct originates in the liver,1,120 the liver can be considered
the most important organ for lymphatic ﬂuid production.
However, the lymphatic vascular system in the liver has been
minimally explored. A small number of studies have reported
on hepatic lymphangiogenesis in pathologic conditions such
as chronic hepatitis, liver ﬁbrosis/cirrhosis, portal hyper-
tension, malignant tumors, and post-transplantation. This
section summarizes these studies.
Chronic hepatitis, liver ﬁbrosis, and cir-
rhosis. Resistance to sinusoidal blood ﬂow increases in
cirrhotic livers because of architectural deformations
including around the portal and central venules. Conse-
quently, sinusoidal hydrostatic pressure is elevated, and
plasma components ﬁltrated through sinusoids (which form
Table 2.Lymphangiogenic and Anti-lymphangiogenic Factors
Experimental model Remarks Reference
Lymphangiogenic
factors
VEGF-A Mouse corneal lymphangiogenesis VEGF-A recruits macrophages,
which promote lymphangiogenesis
by secreting VEGF-C/VEGF-D.
103
Mouse subcutaneous immunization model VEGF-A expression is upregulated
concomitantly with
lymphangiogenesis in LNs of
immunized mice.
117
Oxazolone sensitized delayed-type
hypersensitivity in mouse ear
Systemic blockade of VEGF-A
attenuates lymphangiogenesis
in draining LNs.
181
HSV-1 infection of cornea HSV-1 causes lymphangiogenesis
by promoting infected cells
to secrete VEGF-A.
182
VEGF-C, VEGF-D VEGF-C transgenic mouse VEGF-C promotes LyEC proliferation
and LV enlargement in the skin.
6
Isolated LyEC VEGF-C stimulates survival, growth,
and migration of LyEC.
91
FGF-2–induced corneal lymphangiogenesis VEGFR-3 blockade cancels
lymphangiogenesis.
183
Chronic airway inﬂammation VEGFR-3 blockade cancels
lymphangiogenesis.
184
LPS-induced peritonitis VEGF-C and VEGF-D promote
lymphangiogenesis in diaphragm.
185
Ang 2 Mouse corneal lymphangiogenesis Ang 2 is upregulated in inﬂamed
cornea, and Ang2 blockade inhibits
inﬂammatory lymphangiogenesis.
186
Mouse corneal lymphangiogenesis Ang 2 is expressed in lymphatic
vessels and macrophages in
inﬂamed cornea. Inﬂammatory
lymphangiogenesis of cornea is
suppressed in Ang2 knockout mice.
Ang2 blockade inhibits LyEC
proliferation and capillary tube formation.
187
HGF Canine primary LyEC, rat tail lymphedema HGF promotes proliferation and
migration of LyEC. Weekly HGF gene
transfer improves lymphedema in vivo.
188
LT CCL21 transgenic mouse, RAG knockout
mouse defective in T and B cell
LT overexpression by CCL21 transgene
promotes lymphangiogenesis in thyroid.
T-cell depletion cancels this phenomenon.
189
LTa knockout mouse, LTa transgenic mouse LTa gene deletion decreases LV. Ectopic
LTa expression causes
lymphangiogenesis in tertiary
lymphoid organs.
190
IL1b Mouse corneal lymphangiogenesis IL1b promotes lymphangiogenesis by
upregulating expression of
VEGF-A, VEGF-C, and VEGF-D.
191
IL7 Breast cancer cell lines, subcutaneous
injection of Matrigel and/or IL7 and/or
breast cancer cell lines
IL7 promotes VEGF-D expression
of cell lines in vitro and promotes
lymphangiogenesis in vivo.
192
HECV cell line (originated from human
umbilical cord), subcutaneous
injection of Matrigel
and/or IL7 and/or HECV cell
IL7 promotes expression of Prox1,
LYVE-1, and podoplanin and
proliferation, migration, and tubular
formation of LyEC via upregulation
of VEGF-D.
193
IL8 Human primary LyEC, IL8 transgenic mouse
and Prox1-GFP mouse
IL8 promotes proliferation,
migration, and tube formation of
LyEC. IL8 overexpression
promotes lymphangiogenesis in vivo.
194
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Table 2.Continued
Experimental model Remarks Reference
IL17 Cornea micro pocket assay, autoimmune
ocular disease mouse
IL17 promotes proliferation of
LyEC via upregulation of VEGF-D.
Blockade of IL17 decreases
corneal lymphangiogenesis.
195
IL20 Human telomerase-transfected
dermal LyEC
IL20 promotes proliferation, migration,
and tubular formation of LyEC via
PI3K and mTOR pathways.
196
Anti-lymphangiogenic
factors
TGF-b Human dermal lymphatic microvascular
endothelial cells
TGF-b inhibits LyEC proliferation,
cord formation, migration, expression
of lymphatic markers (LYVE-1, Prox1),
and lymphangiogenesis by
VEGF-A/C via TGF-b type I receptor.
197
Mouse tail skin excision and lymphatic
vessel ligation
TGF-b1 inhibition promotes lymphatic
vessel regeneration. TGF-b1 inhibits
LyEC proliferation and ﬁbrosis.
198
Biopsy specimens from limbs of
secondary lymphedema patients
and mouse tail skin excision
TGF-b1 positive cells increase 3-fold in
human lymphedema specimens.
TGF-b1 inhibition decreases ﬁbrosis,
increases lymphangiogenesis
and lymphatic function.
199
BMP2 Zebraﬁsh BMP2 transgenic model BMP2 inhibits LyEC differentiation
from cardinal veins via
inhibition of Prox1 expression.
200
IFN-a, IFN-g LyEC isolated from pig thoracic duct IFN-a or IFN-g decreases LyEC
proliferation and migration.
Treatment with both IFN-a
and IFN-g promotes LyEC apoptosis.
201
Cervical LNs of T-cell–deprived mouse T cells inhibit lymphangiogenesis
in LNs by secreting IFN-g.
116
IL4, IL13 Mouse LyEC isolated from LNs, human
dermal LyEC, mouse asthma model
IL4 and IL13 inhibit expression of
Prox1 and LYVE-1 and tube
formation of LyEC. Blockade of
IL4 and/or IL13 increases the
density and function of lung
LVs in asthma model.
202
IL27 Human dermal lymphatic microvascular
endothelial cells
IL27 inhibits LyEC proliferation and
migration via STAT1/CXCL10,
CXCL-11 axis.
203
Activin A Subcutaneous injection of melanoma
cell line to mouse
Activin A reduces lymphangiogenesis
in melanoma model and inhibits
sprouting of LyEC via
phosphorylation of SMAD2.
204
FGF-2, ﬁbroblast growth factors-2; HGF, hepatocyte growth factor; HSV-1, herpes simplex virus 1; LN, lymph node;
LPS, lipopolysaccharide; LT, lymphotoxin; LV, lymphatic vessel; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase;
STAT, signal transducer and activator of transcription; TGF, tumor growth factor.
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ﬂuid produced in the liver increases up to 30-fold,121–125
and liver surface lymphatic vessels dilate, as shown by
peritoneoscopic observation.126
Ascites formation in association with cirrhosis is one of
the most recognized clinical manifestations of lymphatic
vascular disorders. How ascites is formed still remains to be
elucidated. Although several theories have been put for-
ward,127–129 the most accepted currently is “the peripheral
arterial vasodilation theory”, also known as “the forwardtheory”.130–132 According to this theory, splanchnic arterial
vasodilation caused by portal hypertension results in
underﬁlling of the splanchnic arterial circulation (hypo-
volemia). In moderate stages, the hypovolemia is compen-
sated for by renal retention of sodium and water. However,
in severe portal hypertension with splanchnic arterial
vasodilation, sodium and water retention is persistent and
leads to leakage of ﬂuid into the peritoneal cavity. When
its amount exceeds the absorption capacity of lymphatic
vessels, ascites results.129,133
Figure 3. Intracellular signaling pathways in lymphangiogenesis. Signaling via VEGF-C/D and VEGFR-3 is the most well-
known pathway for lymphangiogenesis. VEGF-C or VEGF-D binds to its receptor VEGFR-3 in the plasma membrane of
LyECs, which facilitates signal transduction through various intracellular signaling pathways, leading to lymphangio-
genesis. In the liver, activated macrophages in chronic inﬂammatory conditions, such as chronic hepatitis and liver
cirrhosis, secrete VEGF-C and/or VEGF-D. Malignant liver tumors, such as HCC and intrahepatic cholangiocarcinoma, also
secrete VEGF-C and/or VEGF-D. Furthermore, these malignant tumors activate tumor-associated macrophages, which
also secrete VEGF-C and/or VEGF-D. Secreted VEGF-C and VEGF-D are likely related to lymphangiogenesis in liver
diseases through VEGFR-3–mediated pathways.
November 2016 Hepatic Lymphatic Vascular System 741On a related note, impaired lymphatic drainage in the
splanchnic and peripheral regions was reported in cirrhotic
rats with ascites. This was accompanied by increased
activity of endothelial NO synthase and production of NO by
LyECs in these regions.134 In addition, smooth muscle cell
coverage of lymphatic vessels in these regions was signiﬁ-
cantly decreased. Treatment of these cirrhotic rats with an
NO synthase inhibitor improved lymphatic drainage,
decreased ascites volume, and increased smooth muscle cell
coverage. This study thus demonstrates a role for NO in the
impairment of lymphatic vessels in splanchnic and periph-
eral regions and in the development of ascites. It is not
known whether lymphatic vessels in human cirrhotic livers
show similar pathologic features.
The occurrence of hepatic lymphangiogenesis was
reported for the ﬁrst time in liver ﬁbrosis and cirrhosis byVollmar et al135 in 1997. They found lymphatic vessels to be
increased and enlarged in rat liver cirrhosis induced by
carbon tetrachloride (CCl4). These observations were
conﬁrmed the following year in patients with chronic viral
hepatitis/cirrhosis.136
Microarray analysis demonstrated a 4-fold increase in
VEGF-D expression in endothelial cells from CCl4-induced
cirrhotic rat livers as compared with control rat livers.
Because VEGF-D is a well-known lymphangiogenic factor
that binds to VEGFR-3,137 which is also highly expressed in
the LyECs of these cirrhotic rats,5 increased VEGF-D could
be associated with the lymphangiogenesis observed in liver
cirrhosis (Figure 3).
Lymphangiogenesis also occurs in idiopathic portal
hypertension in human patients.138 It was presumed that
increased lymph production that was due to increased
742 Tanaka and Iwakiri Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 6portal pressure caused lymphangiogenesis. In 2 rat
models of portal hypertension (portacaval shunt and
portal vein ligation), upregulation of Vegfr-3 expression
was observed, leading us to speculate the occurrence of
lymphangiogenesis.139 However, the signiﬁcance and
mechanism of hepatic lymphangiogenesis, including in
chronic hepatitis and liver ﬁbrosis and cirrhosis, remain
unknown.
Malignant tumors. Lymphatic vessels play a pivotal role
in the pathogenesis of malignant tumors by serving as a
pathway through which tumor cells metastasize. The inci-
dence of lymph node metastasis differs among tumors. For
example, it is 5.1% in HCC and 45.1% in intrahepatic chol-
angiocarcinoma. The prognosis of tumor-bearing patients
with lymph node metastasis is worse than in cases without
such metastasis.140,141 Many malignant tumors secrete
lymphangiogenic factors such as VEGF-C and VEGF-D and
promote lymphangiogenesis in their adjacent tissues, which
helps tumor cells to metastasize to lymph nodes,142 and
many studies have demonstrated that tumor-associated
macrophages play a vital role in lymphangiogenesis in ma-
lignant tumors by secreting VEGF-C and VEGF-D.102,143–145
In intrahepatic cholangiocarcinoma, the lymphatic vessel
density of surgically resected tumors was positively corre-
lated with the incidence of lymphatic metastasis.146 In HCC,
VEGF-C expression was positively correlated with the size of
tumors and the number of extrahepatic metastases and was
negatively correlated with disease-free survival time.147
Thus, blockade of VEGF-C may be a potential therapeutic
strategy against malignant tumors. A VEGF-C neutralizing
antibody (VGX-100) is now the subject of a Phase I clinical
trial for adult patients with advanced or metastatic solid
tumors (NCT01514123).148
Post-transplant lymphangiogenesis. In solid organ
transplants, lymphatic vessel connections between the graft
and the recipient are interrupted. Because lymphatic vessels
are essential for adaptive immunity, the association be-
tween lymphangiogenesis and graft rejection has received
considerable attention. Post-transplant lymphangiogenesis
in grafts was associated with acute cellular graft rejection in
transplants of various organs (kidney,149–151 heart,152 and
lung153) in humans. However, the pathologic role of post-
transplant lymphangiogenesis in graft rejection remains
unclear.151 Post-transplant lymphangiogenesis could be
detrimental if newly formed lymphatic vessels promote
antigen presentation in draining lymph nodes and provoke
alloimmune responses that result in graft rejection. On the
other hand, these newly formed lymphatic vessels could be
beneﬁcial if they efﬁciently clear immune cells. In a rat
model of liver transplantation, post-transplant lym-
phangiogenesis in grafts was associated with long-term
survival of recipients for more than 90 days.154 In addi-
tion, rats that had failed grafting by 11 days with acute
cellular rejection and antibody-mediated rejection showed
disappearance of lymphatic vessels from severely rejected
areas, suggesting that lymphatic vessels have an important
role in mitigation of inﬂammation at least in the early stage
of transplantation. Further investigations to determine the
mechanism and the time course of clearance of inﬁltratingimmune cells by lymphatic vessels, especially in the early
post-transplant period, may help increase transplant
success.Conclusions and Perspective
The lymphatic vascular system has been poorly studied
in the liver. To drive research in this area, it is essential to
identify better markers for LyECs that do not overlap with
markers for LSECs, hepatocytes, and other liver cells. The
development of experimental models for studying the
lymphatic vascular system in postnatal livers will be
important in examining its role and molecular mechanisms
in physiological and pathophysiological conditions. Although
this ﬁeld is wide open, it may be helpful to identify speciﬁc
questions particularly in need of study.
First, the mechanism of hepatic lymphangiogenesis is
largely unknown. The VEGF-C/VEGFR-3 axis is considered
the most potent signaling pathway that regulates lym-
phangiogenesis in other organs.95 However, cellular sources
of VEGF-C and VEGFR-3 have not been fully identiﬁed in the
liver. Furthermore, as shown in Table 2, many other mole-
cules are reported to regulate lymphangiogenesis. These
molecules are mostly observed in the liver in physiological
and pathophysiological conditions. It would be worth
characterizing these molecules in relation to hepatic
lymphangiogenesis.
Second, although the relationship between the lymphatic
vascular system and metastasis is well-known and the
growth of lymphatic capillaries in liver tumors has been
observed, the role of lymphatic capillary growth in the
development and progression of liver tumors is largely
unknown. As for angiogenesis, it would be interesting to
investigate lymphangiogenesis in liver cancer.
Third, inﬂammation is closely related to the develop-
ment of many liver diseases, and inﬁltrating immune cells
are drained to lymphatic vessels. Thus, it would be inter-
esting to examine lymphangiogenesis in relation to inﬂam-
mation in the liver. It is also unknown how immune cells
recognize lymphatic vessels at the time of migration.
Elucidation of these mechanisms may help in the develop-
ment of anti-inﬂammatory strategies that facilitate immune
cell clearance.
Fourth, although LyECs are derived from cardinal
veins8,81 and LSECs are derived from the septum trans-
versum,155 LyECs and LSECs have many similarities. Both
LyECs and LSECs express LYVE-1.40–43 VAP-1, a type II
transmembrane protein that supports leukocyte adhesion,
and reelin, a glycoprotein that is associated with embryonic
development, are also expressed in both LyECs and
LSECs.156,157 Furthermore, under normal conditions, neither
LyECs nor LSECs are associated with basement membranes.
Examining the similarities and differences between these 2
types of endothelial cells could help to understand endo-
thelial cell–related liver function.
In summary, the lymphatic vascular system in the liver is
a large open area for investigation.158 More research will
signiﬁcantly advance our understanding of liver physiology
and pathophysiology and in turn contribute to the
November 2016 Hepatic Lymphatic Vascular System 743development of new therapeutic strategies for many liver
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